Urinary Peptide Tests for Kidney Disease: What's Closest to Clinical Use?
A systematic review of 62 studies identified eight peptide biomarkers and several multi-peptide classifiers that could detect chronic kidney disease earlier than current blood and urine tests.
Quick Facts
What This Study Found
From a systematic search of 3,668 articles, 62 studies met inclusion criteria and identified eight established single peptide biomarkers plus several proteomic classifiers (including CKD273 and IgAN237) for chronic kidney disease. These urinary peptide biomarkers show potential to detect kidney disease earlier than the current standard tests — serum creatinine and urinary albumin — which have known blind spots in early-stage kidney impairment.
Proteomic classifiers that analyze patterns across hundreds of peptides simultaneously (like CKD273, which uses 273 urinary peptides) are emerging as the most promising approach for clinical implementation.
Key Numbers
3,668 articles screened · 62 studies included · 8 single peptide biomarkers · CKD273 (273-peptide classifier) · IgAN237 (237-peptide classifier) · 5-year literature window
How They Did This
PRISMA-compliant systematic review searching the Web of Science database (October 2022) for English-language, full-text, original human studies published within the last 5 years and cited at least 5 times per year. Three independent authors performed abstract and full-text analysis. Excluded: animal models, transplant studies, metabolite/miRNA/exosomal vesicle studies.
Why This Research Matters
Chronic kidney disease affects hundreds of millions of people worldwide, and current diagnostic tests miss early-stage disease when intervention would be most effective. Urinary peptide biomarkers could detect kidney damage before irreversible loss of function occurs. This systematic review maps the landscape of what's available and what's closest to clinical use, providing a roadmap for the transition from creatinine-based diagnostics to precision peptide-based detection.
The Bigger Picture
Kidney disease is often called a 'silent killer' because it's usually advanced by the time standard tests catch it. The shift toward urinary peptidomics — scanning entire peptide profiles rather than single markers — represents a broader trend in precision diagnostics. If validated and adopted clinically, these tools could transform kidney disease from a late-diagnosis condition to one caught and managed early, potentially saving millions from dialysis or transplant.
What This Study Doesn't Tell Us
Limited to the Web of Science database, potentially missing studies indexed only in other databases. The 5-times-per-year citation requirement may exclude newer but important studies. The field is rapidly evolving, and the October 2022 search cutoff means more recent discoveries are not captured. Clinical validation and regulatory approval for most biomarkers discussed remain incomplete.
Questions This Raises
- ?What regulatory hurdles remain before CKD273 or similar proteomic classifiers can be used in routine clinical practice?
- ?Could these urinary peptide panels also predict which kidney disease patients will progress to end-stage disease?
- ?How cost-effective would mass spectrometry-based urinary peptide testing be compared to current creatinine and albumin tests?
Trust & Context
- Key Stat:
- 8 single peptide biomarkers identified Plus multi-peptide classifiers like CKD273 (273 peptides) that could detect kidney disease before standard creatinine and albumin tests
- Evidence Grade:
- Rated high because this is a PRISMA-compliant systematic review with rigorous methodology, three independent reviewers, and clear inclusion/exclusion criteria, covering 62 qualifying studies.
- Study Age:
- Published in 2023 with literature through October 2022. The field of urinary proteomics is advancing rapidly, so newer biomarker discoveries may have emerged since this review.
- Original Title:
- Recent Advances in Urinary Peptide and Proteomic Biomarkers in Chronic Kidney Disease: A Systematic Review.
- Published In:
- International journal of molecular sciences, 24(11) (2023)
- Authors:
- Catanese, Lorenzo, Siwy, Justyna(4), Mischak, Harald(4), Wendt, Ralph, Beige, Joachim, Rupprecht, Harald
- Database ID:
- RPEP-06782
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Why aren't current kidney tests good enough?
Serum creatinine and urinary albumin — the standard tests — don't become abnormal until significant kidney damage has already occurred. By then, much of the kidney's filtering capacity may be irreversibly lost. Peptide biomarkers can detect damage earlier, when intervention could prevent progression.
What is CKD273 and how does it work?
CKD273 is a diagnostic classifier that simultaneously analyzes 273 different peptides in a urine sample using mass spectrometry. The pattern of these peptides creates a 'fingerprint' that can identify chronic kidney disease much earlier than traditional tests.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-06782APA
Catanese, Lorenzo; Siwy, Justyna; Mischak, Harald; Wendt, Ralph; Beige, Joachim; Rupprecht, Harald. (2023). Recent Advances in Urinary Peptide and Proteomic Biomarkers in Chronic Kidney Disease: A Systematic Review.. International journal of molecular sciences, 24(11). https://doi.org/10.3390/ijms24119156
MLA
Catanese, Lorenzo, et al. "Recent Advances in Urinary Peptide and Proteomic Biomarkers in Chronic Kidney Disease: A Systematic Review.." International journal of molecular sciences, 2023. https://doi.org/10.3390/ijms24119156
RethinkPeptides
RethinkPeptides Research Database. "Recent Advances in Urinary Peptide and Proteomic Biomarkers ..." RPEP-06782. Retrieved from https://rethinkpeptides.com/research/catanese-2023-recent-advances-in-urinary
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.